Clinical trials: Conjunctival Diseases
Conjunctivitis, Allergic
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
- Trial name
- NCT00424398
- Testing
- Bepreve, Bepotastine Besilate
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Bausch & Lomb Incorporated
Keratoconjunctivitis Sicca
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02121301
- Testing
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mitotech, SA
Trachoma
Safety and Immunogenicity of a Chlamydia Vaccine CTH522
CHLM-02 was a phase I, double-blind, randomized, placebo-controlled trial of the chlamydia vaccine CTH522. 65 trial participants were randomized into 12 groups and six cohorts (A1 to F2).
- Trial name
- CHLM-02 (NCT03926728)
- Testing
- CTH522-CAF01 IM, CTH522-CAF09b IM, CTH522 ID
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Allergic Conjunctivitis
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT03479307
- Testing
- Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 228 people
- Sponsor
- Faes Farma, S.A.
Rhinitis; Allergic, With Asthma, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00783198
- Testing
- SCH 39641 6 Amb a 1-U, SCH 39641 12 Amb a 1-U
- Volunteers
- 565 people
- Sponsor
- ALK-Abelló A/S
Allergic Conjunctivitis
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
- Trial name
- NCT01119287
- Testing
- Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Alcon Research
Pterygium
The Effect of Bevacizumab (Avastin) on Pterygium
The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth.
- Trial name
- NCT00592176
- Testing
- local injection of bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Glaucoma, Glaucoma Following Surgery
Anterior-segment OCT (AS-OCT) and Intraoperative OCT (iOCT) for Trans- Conjunctival Needle Revision (TCNR)
Trabeculectomy is a very important and commonly performed glaucoma operation. It allows fluid from inside the eye to exit into a space called a bleb located on the surface of the eye under the upper eyelid.
- Trial name
- NCT05790408
- Testing
- Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Dry Eye Syndrome, Tear Film Insufficiency
Tolerability, Safety and Efficacy of Lubricin vs Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye
The objective of the clinical investigation was to evaluate tolerability, safety and efficacy of the tested medical device, eye drop containing Lubricin 150 µg/mL, as compared with a standard sodium hyaluronate 0.13% eye drop…
- Trial name
- NCT02510235
- Testing
- Lubricin, Sodium Hyaluronate
- Where
- 2 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Dompé Farmaceutici S.p.A
Allergic Conjunctivitis
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01743027
- Testing
- AL-4943A ophthalmic solution, Olopatadine hydrochloride ophthalmic solution, 0.2%, Olopatadine hydrochloride ophthalmic solution, 0.1%
- Volunteers
- 902 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.
- Trial name
- NCT05815758
- Testing
- Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Pterygium, Ocular Pain
Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.
Title of the study Efficacy and safety of PRO-155 (Zebesten ofteno®) on inflammation of the conjunctival surface in subjects with grade I-III pterygium vs placebo. Hypothesis H0.
- Conditions
- Pterygium, Ocular Pain, Ocular Inflammation, Post-surgical Inflammation
- Trial name
- PRO-155/IV (NCT03521791)
- Testing
- PRO-155
- Where
- 3 sites in Mexico
- Volunteers
- 166 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Conjunctivitis
Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers
The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers.
- Trial name
- NCT00889252
- Testing
- contact lens with ketotifen, contact lens
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Bacterial Conjunctivitis
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
The objective of this study is to evaluate the safety and efficacy of Besivance (besifloxacin 0.6%) ophthalmic suspension compared to gatifloxacin 0.3% ophthalmic solution when administered three times daily (TID) for seven days…
- Trial name
- NCT01330355
- Testing
- Besivance, Gatifloxacin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Bausch & Lomb Incorporated
Keratoconjunctivitis Sicca
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.
- Trial name
- DROPS (NCT01900249)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 20 sites in United States
- Volunteers
- 204 people
- Sponsor
- Rigel Pharmaceuticals
Allergic Conjunctivitis
Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers
This study is being conducted to evaluate the safety of KetoNaph ophthalmic solution in healthy adult subjects and in pediatric subjects with a history or family history of ocular allergy.
- Trial name
- NCT01159015
- Testing
- KetoNaph, Vehicle
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis, Allergic
Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in…
- Trial name
- NCT01987765
- Testing
- Relestat Ophthalmic Solution 0.05%
- Where
- South Korea
- Volunteers
- 847 people
- Sponsor
- Allergan
Allergic Conjunctivitis
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT03231969
- Testing
- Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Faes Farma, S.A.
Keratoconjunctivitis Sicca, Dry Eye Disease
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye.
- Trial name
- OPUS-1 (NCT01421498)
- Testing
- Lifitegrast
- Where
- 13 sites in United States
- Volunteers
- 588 people
- Sponsor
- Shire
Dry Eye, Dry Eye Syndromes
Tear Production by Nasal Neurostimulation Compared to Active Control
This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones…
- Conditions
- Dry Eye, Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Trial name
- NCT02970799
- Testing
- Intranasal Neurostimulator
- Volunteers
- 27 people
- Sponsor
- Oculeve, Inc.